Sign-up for the Pharmacy Solutions Newsletter for Big Discounts!
Enjoy 10% off for Patient Appreciation Day with code THANKYOU10 on 11/16/2026 only! Shop Now >
Discuss a patient-specific formulation with a pharmacist when you have identified a clinical need that an available FDA-approved medication cannot appropriately meet, such as a documented ingredient allergy or a dosage form the patient cannot use. When you contact a diabetes compounding pharmacy, start with that unmet need and the approved alternatives you have considered. The consultation should establish whether compounding is feasible and clinically justified before you prescribe.
This checklist provides a framework for that discussion. It does not establish the suitability of a particular preparation or replace your assessment, current labeling or formulation-specific evidence. A diabetes diagnosis alone does not establish a need for compounding.
Describe the problem precisely enough for another clinician to assess it. “Needs a different formulation” leaves important questions unanswered. Document which product is unsuitable, the specific barrier and how it affects treatment.
For a hypothetical example, a patient develops swallowing difficulty while taking an oral diabetes medicine. First review whether an appropriate approved dosage form or alternative treatment is available. If an unmet need remains, ask the pharmacist whether a suitable preparation can be made for that medication. Do not assume that every tablet can be crushed or converted to a liquid.
Likewise, an ingredient concern should identify the ingredient and the reported reaction. An allergy, gastrointestinal intolerance and a preference to avoid an excipient call for different clinical discussions. Review the actual product ingredients rather than assuming all marketed versions have the same composition.
The FDA advises using compounded drugs for patients whose medical needs cannot be met by an FDA-approved drug. Frame the request around that patient’s circumstances, without implying that a compounded preparation is inherently safer or more effective.
Pharmacy Solutions’ diabetic care resources for providers describe areas available for formulation discussion. Use that page to identify questions for the pharmacist; a listed capability does not establish appropriateness for your patient. If your practice needs access to provider resources, register for a provider account while preparing your inquiry.
A useful diabetic care compounding consultation begins with a focused clinical summary. Have the following information ready:
Include your practice contact information and identify the clinician who can resolve questions. Send relevant records rather than an unexplained chart export. For patient-specific diabetes formulations, make the intended treatment role clear: managing glucose, addressing a separate symptom or another defined purpose.
Begin a general feasibility inquiry without patient identifiers when those details are not needed. Before transmitting identifiable records, confirm the pharmacy’s designated method for clinical information and follow your organization’s privacy and security procedures. Verify the recipient and transmission details.
HHS permits providers to exchange protected health information for treatment with reasonable safeguards. Do not assume that a general website inquiry or provider registration form is the designated channel for sending a patient’s chart. Ask how the pharmacy wants to receive the information needed for its review.
Ask the pharmacist to separate two questions: Can this preparation be made appropriately, and what evidence supports its intended use? A workable formulation does not by itself demonstrate absorption, clinical effectiveness or equivalence to an approved product.
For the formulation review, ask about ingredient availability, compatibility, stability information, packaging and storage. Confirm the proposed beyond-use date, meaning the point after which the preparation should no longer be used, and whether the patient can manage the handling requirements. These details belong in the discussion before the prescription is finalized.
Then examine the clinical evidence for the specific drug, concentration, dosage form, route and indication. Evidence for an oral medicine does not automatically establish that the same ingredient will provide effective systemic treatment through the skin. Avoid assuming dose equivalence when the route changes.
For a hypothetical podiatry consultation, a request concerning pain in a patient with diabetes should identify the assessed pain condition and intended treatment goal. Ask whether the evidence concerns that condition and the proposed preparation. A formulation discussion does not establish that a topical preparation improves wound healing or substitutes for evaluation of a new foot lesion.
If evidence is limited, record the uncertainty and reconsider the available alternatives. The consultation may reasonably end with a decision to use an approved product, obtain more information or decline the proposed formulation.
Prescriber pharmacist collaboration works best when each next action has an owner. You determine the diagnosis, indication, treatment goals and clinical follow-up. The pharmacist evaluates the prescription and formulation within their professional responsibilities, identifies concerns and communicates what requires clarification. Resolve those questions before dispensing.
If treatment proceeds, document what you will assess and when. For a glucose-lowering treatment, specify how glucose data, hypoglycemia risk and relevant laboratory results will inform follow-up. For a separate symptom, define an appropriate symptom or functional measure. Avoid applying one monitoring schedule to every preparation or indication.
Confirm who will counsel the patient on administration, measuring devices when applicable, storage and the beyond-use date. Give the patient a contact plan for adverse effects, administration difficulties or inadequate response, including urgent-care instructions appropriate to the treatment.
Before closing the consultation, confirm:
Provide the medication, strength, route, intended use and the reason an approved product is unsuitable. Add relevant history, allergies, current medicines and practical administration needs. Confirm a secure channel before sharing identifiable records. The prescriber and pharmacist should decide which additional information is necessary for that patient and preparation.
No. Compounded medications are not FDA-approved. FDA does not review their safety, effectiveness or quality before marketing. They are also distinct from FDA-approved generic drugs. A prescription or a pharmacy’s ability to prepare a formulation does not establish FDA approval or therapeutic equivalence.
Register for a Pharmacy Solutions provider account to request access to provider resources, then contact the pharmacy team to discuss the patient-specific need. Have your clinical question and the approved alternatives you considered ready. Confirm the appropriate channel before sending patient information.
This information is intended for healthcare professional education and does not replace current prescribing information, applicable guidance or individualized clinical judgment. Compounded medications are not FDA-approved. Evaluate the evidence, risks and monitoring requirements for each patient and proposed preparation.
To submit your order, click the “PRINT/SAVE” button located under this pop-up.
You can save the PDF to your computer to fax at a later date or print it now to fax immediately.
Fax your order form to 817-860-6083 for processing.
New to Pharmacy Solutions? Register now